Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NGG1 interacting factor 3 like 1 (NIF3L1) is a highly conserved human protein thought to function as a transcriptional corepressor, primarily through interaction with COPS2, which may contribute to the negative regulation of neuronal differentiation genes. It is widely expressed and has evidence for protein-protein interactions (including self-interaction and binding to specific co-regulators). Although originally mapped to a region associated with juvenile-onset amyotrophic lateral sclerosis, there is currently no proof that NIF3L1 is itself causative for this or any other human disease. No drugs target the protein, and it is not considered a classical drug target in current clinical or pharmaceutical practice.
Not applicable; no drugs target this molecule directly
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NGG1 interacting factor 3 like 1 (NIF3L1).